Acadia Healthcare Company, Inc. $ACHC is Teca Partners LP’s 8th Largest Position

Teca Partners LP grew its position in shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 5.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 467,343 shares of the company’s stock after buying an additional 22,831 shares during the quarter. Acadia Healthcare accounts for 7.3% of Teca Partners LP’s portfolio, making the stock its 8th largest position. Teca Partners LP owned about 0.51% of Acadia Healthcare worth $11,571,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Allworth Financial LP lifted its position in Acadia Healthcare by 676.4% in the 2nd quarter. Allworth Financial LP now owns 1,351 shares of the company’s stock valued at $31,000 after acquiring an additional 1,177 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Acadia Healthcare by 54.8% in the second quarter. EverSource Wealth Advisors LLC now owns 1,404 shares of the company’s stock worth $32,000 after purchasing an additional 497 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of Acadia Healthcare by 501.9% in the third quarter. Hantz Financial Services Inc. now owns 2,185 shares of the company’s stock worth $54,000 after purchasing an additional 1,822 shares during the last quarter. Quent Capital LLC bought a new position in shares of Acadia Healthcare during the third quarter valued at $71,000. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Acadia Healthcare by 639.5% during the second quarter. Steward Partners Investment Advisory LLC now owns 3,372 shares of the company’s stock valued at $77,000 after buying an additional 2,916 shares during the last quarter.

Acadia Healthcare Stock Performance

ACHC traded down $0.24 during trading on Friday, hitting $23.92. The company’s stock had a trading volume of 430,375 shares, compared to its average volume of 3,897,160. The business’s 50 day simple moving average is $16.61 and its 200-day simple moving average is $18.77. The firm has a market cap of $2.21 billion, a PE ratio of -1.97, a P/E/G ratio of 8.07 and a beta of 0.74. Acadia Healthcare Company, Inc. has a one year low of $11.43 and a one year high of $31.04. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of 1.27.

Acadia Healthcare (NASDAQ:ACHC) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. Acadia Healthcare had a negative net margin of 33.29% and a positive return on equity of 6.53%. The firm had revenue of $821.46 million during the quarter, compared to the consensus estimate of $800.10 million. During the same quarter in the previous year, the firm posted $0.64 EPS. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. As a group, sell-side analysts predict that Acadia Healthcare Company, Inc. will post 3.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Guggenheim decreased their target price on Acadia Healthcare from $27.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, February 23rd. Barclays raised their price target on shares of Acadia Healthcare from $14.00 to $20.00 and gave the company an “equal weight” rating in a report on Tuesday, March 3rd. Royal Bank Of Canada boosted their price objective on shares of Acadia Healthcare from $17.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. UBS Group increased their price objective on shares of Acadia Healthcare from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, Leerink Partners raised their target price on shares of Acadia Healthcare from $14.00 to $22.00 and gave the stock a “market perform” rating in a report on Thursday, February 26th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $21.15.

Trending Headlines about Acadia Healthcare

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Appointment to board may provide governance/operational expertise — Acadia named Daniel Cancelmi to its Board of Directors, a routine governance move that can be seen as positive for oversight and strategy. Acadia Healthcare Appoints Daniel Cancelmi to Board of Directors
• Neutral Sentiment: Short-interest data reported for March appears anomalous (entries show 0 shares / NaN changes and 0.0 days-to-cover), so there’s no clear signal from short sellers on near-term positioning; treat these figures as unreliable until corrected by exchanges.
• Negative Sentiment: Zacks Research cut multiple near-term and multi-year EPS estimates and left a “Hold” rating — the firm trimmed Q2 2026 to $0.49 (from $0.66), pushed FY2026 down to $1.48 (from $1.85), and lowered FY2027 to $1.55 (from $1.96), along with reductions across several quarters. These coordinated cuts increase downside risk to sentiment and may pressure the stock as investors reprice earnings expectations.
• Negative Sentiment: Broad, repeated downward revisions across several future quarters (Q1–Q4 2026 and Q1–Q4 2027) signal potential slower-than-expected operational performance or margin pressure versus prior assumptions; combined with the company’s negative net margin and recent EPS volatility, this raises execution risk for investors.

Acadia Healthcare Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.